SUN PHARMA ADV.RES.CO.LTD

{
    "company_profile": "Sun Pharma Advanced Research Company Limited is an India-based clinical-stage biopharmaceutical company that focuses on developing therapeutics to improve standards of care for patients worldwide. The Company\u2019s therapeutic focus is in the area of oncology, neurology and immunology. Its lead oncology programs include vodobatinib (SCO-088), a BCR-ABL targeting tyrosine kinase inhibitor for refractory chronic myelogenous leukemia, and an anti-MUC-1 antibody-drug conjugate (ADC) with the potential to treat multiple cancers. The Company\u2019s other programs include Sezaby for the treatment of neonatal seizures, Vodobatinib for the treatment of neurodegenerative disorders (SCC-138), Vibozilimod for the treatment of autoimmune disorders (SCD-044), SCD-153 for the treatment of alopecia areata, SBO-154 for multiple cancer indications and SCO-155 for treatment of cancer. SBO-154 is an anti MUC1 ADC being developed for multiple tumor types expressing MUC1.",
    "sector": "Diversified",
    "sector_market_cap_inr": {
        "value": 6412.55,
        "unit": "crore",
        "formatted": "6,412.55 Cr"
    },
    "sector_market_cap_usd": {
        "value": 712.51,
        "unit": "million",
        "formatted": "$712.51M"
    }
}